Tirzepatide for Stroke Prevention
GLP-1 medications address multiple stroke risk factors simultaneously through weight loss, blood pressure reduction, improved lipid profiles, and better glycemic control. Tirzepatide (Zepbound/Mounjaro) is a dual GLP-1/GIP receptor agonist with 20-22% average body weight loss — the highest of any GLP-1 medication.
How Tirzepatide Helps with Stroke Prevention
Tirzepatide targets both GLP-1 and GIP receptors for enhanced appetite control and metabolic effects. This dual mechanism produces the highest weight loss of any available GLP-1 medication. For patients with stroke prevention, the significant weight loss translates to meaningful improvements in condition outcomes.
GLP-1 medications address multiple stroke risk factors simultaneously through weight loss, blood pressure reduction, improved lipid profiles, and better glycemic control. The SURMOUNT-1 clinical trial demonstrated that tirzepatide at the highest dose produces an average weight loss of 22.5% of body weight over 72 weeks.
Clinical Evidence for Stroke Prevention
Stroke Prevention affects approximately 795,000 strokes occur annually in the US with obesity being a top modifiable risk factor. Tirzepatide's dual receptor mechanism provides particularly strong metabolic benefits that extend beyond weight loss, including improved insulin sensitivity, better lipid profiles, and reduced inflammation.
Tirzepatide Dosing for Stroke Prevention
Tirzepatide is administered as a once-weekly subcutaneous injection. Treatment starts at 2.5mg and can increase to 5mg, 7.5mg, 10mg, 12.5mg, or 15mg based on response and tolerability. Each dose increase occurs at 4-week intervals.
Cost of Tirzepatide for Stroke Prevention
Compounded tirzepatide costs $199-449/month through telehealth providers. Brand-name Zepbound costs $1,100+/month without insurance. The higher cost compared to semaglutide may be justified by the greater average weight loss.